BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8313355)

  • 1. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
    Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
    Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38.
    Thomas SM; Zeng Q; Epperly MW; Gooding WE; Pastan I; Wang QC; Greenberger J; Grandis JR
    Clin Cancer Res; 2004 Oct; 10(20):7079-87. PubMed ID: 15501988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
    Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
    Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
    Pai LH; Gallo MG; FitzGerald DJ; Pastan I
    Cancer Res; 1991 Jun; 51(11):2808-12. PubMed ID: 2032221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
    Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
    Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small chimeric toxins containing only transforming growth factor alpha and domain III of Pseudomonas exotoxin with good antitumor activity in mice.
    Kihara A; Pastan I
    Cancer Res; 1994 Oct; 54(19):5154-9. PubMed ID: 7923133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
    Yuan X; Tabassi K; Williams JA
    Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
    Hagan M; Yacoub A; Dent P
    Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
    El-Obeid A; Hesselager G; Westermark B; Nistér M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
    Ekstrand AJ; James CD; Cavenee WK; Seliger B; Pettersson RF; Collins VP
    Cancer Res; 1991 Apr; 51(8):2164-72. PubMed ID: 2009534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
    Slagel DE; Feola J; Houchens DP; Ovejera AA
    Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
    De Jong KP; Stellema R; Karrenbeld A; Koudstaal J; Gouw AS; Sluiter WJ; Peeters PM; Slooff MJ; De Vries EG
    Hepatology; 1998 Oct; 28(4):971-9. PubMed ID: 9755233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
    Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
    Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.